InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.750 0.01 (1.32%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$204 Appendix 4G 31 Aug 2020 5:29PM $0.445 $0.750 risen by 68.54%
$204 Appendix 4C - Quarterly 31 Jul 2020 7:18PM $0.345 $0.750 risen by 117.39%
$204 CelGro Nerve Repair AUS Regulatory Application Submitted 30 Jul 2020 9:23AM $0.340 $0.750 risen by 120.59%
$204 Appendix 2A and Notice Under Section 708A 16 Jul 2020 9:28AM $0.355 $0.750 risen by 111.27%
$204 Orthocells Ortho-ATI Shows 87.5% Success Rate 9 Jul 2020 9:36AM $0.340 $0.750 risen by 120.59%
$204 Recruitment Complete - Ortho-ATI Shoulder Tendon Study 30 Jun 2020 9:10AM $0.315 $0.750 risen by 138.10%
$204 Change of Director's Interest Notice LW 17 Jun 2020 5:11PM $0.350 $0.750 risen by 114.29%
$204 Appendix 3G 17 Jun 2020 5:07PM $0.350 $0.750 risen by 114.29%
$204 Initial Director's Interest Notice LW 10 Jun 2020 7:04PM $0.360 $0.750 risen by 108.33%
$204 Orthocell Appoints Executive Director Leslie Wise 10 Jun 2020 9:21AM $0.355 $0.750 risen by 111.27%
$204 CelGro US 510(k) Submission Completed 12 May 2020 9:35AM $0.365 $0.750 risen by 105.48%
$204 Appendix 4C - Quarterly 30 Apr 2020 5:05PM $0.335 $0.750 risen by 123.88%
$204 Successful Rotator Cuff Regeneration Publication 2 Apr 2020 9:23AM $0.270 $0.750 risen by 177.78%
$204 Successful CelGro US Bone Repair Study 11 Mar 2020 9:36AM $0.305 $0.750 risen by 145.90%
$204 Half Yearly Report and Accounts 25 Feb 2020 4:45PM $0.430 $0.750 risen by 74.42%
$204 Appendix 2A and Notice Under Section 708A 19 Feb 2020 7:33PM $0.480 $0.750 risen by 56.25%
$204 Initial Director's Interest Notice MC 11 Feb 2020 7:40PM $0.480 $0.750 risen by 56.25%
$204 Orthocell Board Update 11 Feb 2020 9:42AM $0.490 $0.750 risen by 53.06%
$204 Orthocell receives new patents for CelGro 5 Feb 2020 9:45AM $0.485 $0.750 risen by 54.64%
$204 Appendix 4C - Quarterly 31 Jan 2020 9:54AM $0.455 $0.750 risen by 64.84%
$204 Orthocell receives A$2.9m R&D tax incentive refund 15 Jan 2020 9:28AM $0.475 $0.750 risen by 57.89%
$204 Appendix 3B - SPP 30 Dec 2019 11:22AM $0.495 $0.750 risen by 51.52%
$204 Share Purchase Plan Update 27 Dec 2019 7:00PM $0.475 $0.750 risen by 57.89%
$204 Appendix 2A and Notice Under Section 708A 17 Dec 2019 6:34PM $0.480 $0.750 risen by 56.25%
$204 US Nerve Repair Study Design Meets FDA Requirements 16 Dec 2019 9:59AM $0.480 $0.750 risen by 56.25%

451 - 475 of 771 results

Page 19 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.